We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer says it plans to begin sales of a biosimilar version of Remicade in late November, despite Janssen’s appeal of a ruling that invalidated its patent covering the arthritis therapy. Read More
Switzerland’s Novartis is shuttering several of its research operations in Switzerland and China, eliminating 175 jobs, in an effort to centralize control of its drug discovery programs and curb costs. Read More
The UK’s price watchdog is recommending reimbursement for AstraZeneca’s Tagrisso as a second-line treatment for an aggressive form of lung cancer. Read More
British drugmaker GlaxoSmithKline will pay $20 million to settle the U.S. Securities and Exchange Commission’s charges that the company bribed healthcare professionals to boost drug sales in China. Read More
The Indian government has revised its list of essential medicines, removing price caps on dozens of drugs in a number of therapeutic classes. Read More
The United Nations High-Level Panel on Access to Medicine is proposing that governments rely on compulsory licenses to improve patient access to medicines in a highly anticipated report that has been met with dismay from industry. Read More
A European Parliament committee is proposing that the European Commission promote transparency in private research to foster better access to medicines across the EU. Read More
The UK Court of Appeal affirmed an earlier ruling that invalidates Pfizer’s patent claims for Lyrica, saying generic versions will not lead to any infringement. Read More
The UK’s price watchdog is not recommending Janssen’s Imbruvica for the treatment of Waldenstrom's macroglobulinemia, a rare type of non-Hodgkin's lymphoma. Read More
Accessing a company’s policy on expanded access might be easier said than done, as most companies fail to post this information on their websites, a recent analysis found. Read More